<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17525" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Androgen Replacement</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sizar</surname>
            <given-names>Omeed</given-names>
          </name>
          <aff>St. Lucie Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Stephen W.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pico</surname>
            <given-names>Jose</given-names>
          </name>
          <aff>Saint Lucie Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Omeed Sizar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Leslie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jose Pico declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>11</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17525.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Testosterone is FDA-approved as replacement therapy in men with low testosterone levels and those with symptoms of hypogonadism. Symptoms highly suggestive of hypogonadism include fewer or diminished spontaneous erections, decreased nocturnal penile tumescence, low libido, sparse beard growth, and shrinking testes. In males, the normal range for early morning testosterone is between 300 ng/dL to 1000 ng/dL but may vary from laboratory to laboratory. Clinicians must distinguish between primary (testicular) and secondary (pituitary-hypothalamic) hypogonadism. This&#x000a0;review discusses&#x000a0;the mechanism of action, adverse event profile, and other key factors (eg, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent to interprofessional team members who use exogenous testosterone to treat hypogonadism.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients who may benefit from androgen replacement therapy based on clinical indications and assessment of hormone levels.</p></list-item><list-item><p>Differentiate different types of androgen replacement therapies, such as testosterone preparations, and understand their pharmacokinetics, dosing, and administration routes.</p></list-item><list-item><p>Assess the therapeutic response to androgen replacement therapy by regularly monitoring hormone levels, symptom improvement, and potential adverse effects.</p></list-item><list-item><p>Select the optimal formulation, dosage, and delivery method of androgen replacement therapy based on patient preferences, adherence, and clinical considerations.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17525&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17525">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17525.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Hypogonadism occurs in 19% of men in their 60s, 28% of men in their 70s, and 49% of men in their 80s.<xref ref-type="bibr" rid="article-17525.r1">[1]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Testosterone is FDA-approved as replacement therapy in men with at least two documented low serum testosterone levels and symptoms associated with hypogonadism.<xref ref-type="bibr" rid="article-17525.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Testosterone is also FDA-approved for use in symptomatic congenital or acquired hypogonadotropic hypogonadism (when there is a pituitary-hypothalamic injury, LHRH deficiency, or gonadotropin deficiency) resulting from tumors, trauma, or radiation who meet the above criteria.</p>
          </list-item>
        </list>
        <p>Testosterone should not be used for men seeking to produce a pregnancy as it significantly decreases sperm production. Instead, clomiphene or human chorionic gonadotropin can increase testosterone levels without negatively affecting sperm production or fertility.<xref ref-type="bibr" rid="article-17525.r3">[3]</xref></p>
        <p>Distinguishing between primary (testicular) and secondary (pituitary-hypothalamic) hypogonadism is essential. Symptoms highly suggestive of hypogonadism include fewer or diminished spontaneous erections, decreased nocturnal penile tumescence, low libido, sparse beard growth, and shrinking testes. In males, the normal range for early morning testosterone is between 300 ng/dL to 1000 ng/dL but may vary from laboratory to laboratory.<xref ref-type="bibr" rid="article-17525.r4">[4]</xref></p>
        <p>Hypogonadism is diagnosed when the morning serum testosterone level is less than 300 ng/dL. However, clinical&#x000a0;judgment is required when diagnosing hypogonadism in a patient with testosterone levels in the normal range but persistent testosterone deficiency symptoms.<xref ref-type="bibr" rid="article-17525.r5">[5]</xref>&#x000a0;In&#x000a0;senior men, one should aim for testosterone levels between 500 and 800 ng/dL, while young adults should aim for testosterone levels between 600 and 900 ng/dL.</p>
        <p>Initial laboratory testing should include&#x000a0;2 early morning (8 AM to 10 AM) serum testosterone measurements. In addition, certain studies should be ordered to rule out secondary hypogonadism if both measurements are low. Further testing includes FSH (follicle-stimulating hormone), LH (luteinizing hormone), prolactin, TSH (thyroid-stimulating hormone), complete blood count (CBC), PSA (prostate-specific antigen) for men older than 40 years, and a comprehensive metabolic panel (CMP).</p>
        <p>Further testing to assess free or bioavailable testosterone is necessary in cases of low normal testosterone with clinical symptoms. These tests include&#x000a0;sex hormone-binding globulin (SHBG) and albumin to calculate the bioavailable testosterone, which can be affected by obesity, type 2 diabetes, hypothyroidism, and liver disease. Semen analyses, pituitary MRI, testicular ultrasound and biopsy, and genetic studies are options if there is clinical suspicion of a secondary&#x000a0;cause.<xref ref-type="bibr" rid="article-17525.r2">[2]</xref></p>
        <p>For more information on diagnosing male hypogonadism, see&#x000a0;the companion StatPearls reference article on "Male Hypogonadism" and the American Urological Association Guideline: Evaluation and Management of Testosterone Deficiency (2018).<xref ref-type="bibr" rid="article-17525.r2">[2]</xref><xref ref-type="bibr" rid="article-17525.r3">[3]</xref>&#x000a0;Testosterone therapy is not FDA-approved to treat low libido in women.</p>
      </sec>
      <sec id="article-17525.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Testosterone has many biological effects as it can act as&#x000a0;3 hormones.&#x000a0;Testosterone can&#x000a0;act directly on the androgen receptors or indirectly in cells and tissues via conversion to dihydrotestosterone&#x000a0;(DHT) by the enzyme 5-alpha reductase. Finally, testosterone can act as an estrogen following conversion by aromatase to estradiol.&#x000a0;</p>
        <p>In many tissues, the activity of testosterone depends on its reduction to DHT, which binds to cytosol receptor proteins. When transported to the cell nucleus, this steroid-receptor complex initiates transcription events and cellular changes related to androgen action. These three actions are crucial to understanding the therapeutic indications and adverse effects of androgen replacement therapy.<xref ref-type="bibr" rid="article-17525.r6">[6]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Testosterone cypionate and enanthate injected IM are absorbed slowly, and hence, they can be given less frequently, although weekly injections are optimal to minimize supernormal levels. Most of the testosterone in plasma (98%) is bound to&#x000a0;globulin.&#x000a0;The distribution between free and bound forms depends on the amount of this&#x000a0;testosterone-estradiol binding globulin in the plasma. The&#x000a0;half-life is directly proportional to the free testosterone concentration in plasma.&#x000a0;</p>
        <p>The main difference between injectable testosterone cypionate and enanthate is the carrier oil. Enanthate dissolves in sesame seed oil, which is very viscous. This takes longer to prepare, draw into the syringe, and inject.&#x000a0;Enanthate is also more likely to cause lumps. Cypionate uses olive oil as a carrier, which is far less viscous and easier to inject. Otherwise, the two formulations are used almost interchangeably.</p>
        <p>The half-life of IM testosterone cypionate is&#x000a0;approximately eight days,&#x000a0;and enanthate is about the same at seven days. Most testosterone, about 90%, is excreted in the urine as glucuronic or sulfuric acid conjugates of testosterone, and it is converted into an inactive form by the liver.<xref ref-type="bibr" rid="article-17525.r7">[7]</xref></p>
      </sec>
      <sec id="article-17525.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Fertility Preserving Therapy</bold>
</p>
        <p>Testosterone replacement should not be used in patients actively trying to produce a pregnancy or which preserve their fertility and sperm counts. Testosterone supplementation reduces sperm counts and spermatogenesis. Ten percent of men on testosterone replacement therapy will not recover their spermatogenesis even after testosterone supplement treatment has ceased.<xref ref-type="bibr" rid="article-17525.r8">[8]</xref> Fortunately, there are a few options available.</p>
        <p>Clomiphene citrate can effectively increase testosterone levels in symptomatic hypogonadal men who wish to maintain their fertility and sperm counts.<xref ref-type="bibr" rid="article-17525.r3">[3]</xref><xref ref-type="bibr" rid="article-17525.r9">[9]</xref><xref ref-type="bibr" rid="article-17525.r10">[10]</xref> Clomiphene increases FSH and LH levels by stimulating the pituitary gland. Since FSH levels are maintained, sperm production is not reduced. The dosing&#x000a0;information is given below.<xref ref-type="bibr" rid="article-17525.r3">[3]</xref><xref ref-type="bibr" rid="article-17525.r9">[9]</xref><xref ref-type="bibr" rid="article-17525.r10">[10]</xref>&#x000a0;</p>
        <p>Clomiphene citrate 25 mg daily may be added to testosterone replacement therapy to help maintain FSH levels and sperm counts.<xref ref-type="bibr" rid="article-17525.r9">[9]</xref><xref ref-type="bibr" rid="article-17525.r11">[11]</xref>&#x000a0;This medication will not effectively raise testosterone levels in men with primary hypogonadism (testicular failure), identified by elevated LH levels in hypogonadal men. Clomiphene is recommended in hypogonadal men who already have low sperm counts.<xref ref-type="bibr" rid="article-17525.r8">[8]</xref><xref ref-type="bibr" rid="article-17525.r12">[12]</xref></p>
        <p>Human chorionic gonadotropin (hCG) has a similar effect and is FDA-approved for use in men with symptomatic testosterone deficiency, often those with hypogonadotropic hypogonadism. Human chorionic gonadotropin has a similar effect as luteinizing hormone (LH) but enjoys a 36-hour half-life compared to just 30 minutes for LH. The typical dose is 3,000 IU every other day. If LH is elevated, hCG supplementation will not effectively raise testosterone levels.</p>
        <p>Using hCG or clomiphene and testosterone replacement therapy can help preserve testicular size and male fertility.<xref ref-type="bibr" rid="article-17525.r8">[8]</xref><xref ref-type="bibr" rid="article-17525.r12">[12]</xref></p>
        <p>
<bold>Testosterone Replacement Therapy</bold>
</p>
        <p>There are many formulations for testosterone. The&#x000a0;2 most popular options are transdermal gels and intramuscular (IM) injections.&#x000a0;Clinicians should note the differences and&#x000a0;adverse effects when choosing the optimal testosterone delivery modality for patients who qualify for treatment. There are many ways to administer testosterone, including oral, buccal, transdermal (gel, patch, solution, pellet), and IM injections. Typically, a maximum of&#x000a0;6 months of therapy may be prescribed per prescription.</p>
        <p>Oral testosterone tablets such as methyltestosterone should generally&#x000a0;not be used to treat testosterone deficiency due to significant hepatic&#x000a0;adverse&#x000a0;effects and highly variable efficacy compared with other formulations.<xref ref-type="bibr" rid="article-17525.r2">[2]</xref><xref ref-type="bibr" rid="article-17525.r3">[3]</xref>&#x000a0;The exception is oral&#x000a0;testosterone undecanoate, which was FDA-approved and became commercially available in the US in February 2020. Early clinical studies show efficacy in maintaining serum testosterone levels without significant side effects or hepatic toxicity.<xref ref-type="bibr" rid="article-17525.r13">[13]</xref><xref ref-type="bibr" rid="article-17525.r14">[14]</xref><xref ref-type="bibr" rid="article-17525.r15">[15]</xref>&#x000a0;Patient satisfaction with this new oral therapy appears higher than with alternative testosterone supplementation treatments.<xref ref-type="bibr" rid="article-17525.r16">[16]</xref></p>
        <p>The buccal form should not be chewed or swallowed.&#x000a0;This dose form is no longer available in the US.</p>
        <p>The FDA discontinued testosterone solutions in 2017 due to&#x000a0;the high incidence of abuse by athletes and bodybuilders.</p>
        <p>A nasal testosterone gel has now been FDA-approved in the United States.&#x000a0;The gel&#x000a0;must be applied three times daily, which many patients find inconvenient.</p>
        <p>Subcutaneous testosterone pellets, typically 2 to 6, are surgically placed every 3 to 6 months into the subdermal fat of the buttocks, abdominal wall, or thigh. They are not routinely recommended due to limited data on maintaining the serum testosterone concentrations during treatment and the need for repeated surgeries to maintain levels.</p>
        <p>Transdermal testosterone formulations, including testosterone gels, patches, pellets, and intramuscular testosterone injections, are the most popular dosage forms of testosterone supplementation in symptomatic hypogonadal men.</p>
        <p>Testosterone gels are generally the recommended formulation due to patient preference, cost, convenience, minimal hormonal level variability, and insurance coverage. The chief advantage of gels is maintaining&#x000a0;stable serum testosterone concentrations, resulting in stable libido, energy, and mood. There are various formulations of testosterone gels. These gels should be applied to&#x000a0;the shoulder, upper arms, or abdomen, not the scrotum. A study showed that the bioavailability of testosterone gel is 30% lower when applied to the abdomen than to the arms and shoulders.<xref ref-type="bibr" rid="article-17525.r17">[17]</xref>&#x000a0;Due to the high dosage variability, commercial preparations are preferred over gels produced by compounding pharmacies.<xref ref-type="bibr" rid="article-17525.r2">[2]</xref></p>
        <p>Intramuscular injections of testosterone include testosterone enanthate and testosterone cypionate. These injections are&#x000a0;generally&#x000a0;recommended at initial doses of 100 mg every week.<xref ref-type="bibr" rid="article-17525.r3">[3]</xref><xref ref-type="bibr" rid="article-17525.r18">[18]</xref>&#x000a0;This minimizes supernormal peak levels.</p>
        <p>In 2014, the FDA approved an extra-long-acting intramuscular injection form of testosterone called testosterone undecanoate, which is dosed&#x000a0;at 750 mg, followed by a second dose&#x000a0;4 weeks later and subsequent doses every&#x000a0;10 weeks.<xref ref-type="bibr" rid="article-17525.r19">[19]</xref>&#x000a0;Testosterone undecanoate is not the&#x000a0;first-line treatment of choice but is generally&#x000a0;used when patients do not have access to other forms of therapy.<xref ref-type="bibr" rid="article-17525.r2">[2]</xref></p>
        <p>
<bold>Testosterone Therapy for Hypogonadal Men With Prostate Cancer</bold>
</p>
        <p>Surprisingly, no conclusive evidence exists that properly dosed and monitored testosterone therapy promotes prostate cancer growth.<xref ref-type="bibr" rid="article-17525.r2">[2]</xref><xref ref-type="bibr" rid="article-17525.r3">[3]</xref><xref ref-type="bibr" rid="article-17525.r20">[20]</xref>&#x000a0;This also applies to patients with low-risk, low-grade cancer on active surveillance and those with High-Grade PIN.<xref ref-type="bibr" rid="article-17525.r20">[20]</xref>&#x000a0;</p>
        <p>In patients who are post-radical prostatectomy, there is limited available data, but testosterone therapy appears to be safe in carefully selected patients if they have favorable risk factors, negative surgical margins, and undetectable PSA levels for at least two years.<xref ref-type="bibr" rid="article-17525.r2">[2]</xref><xref ref-type="bibr" rid="article-17525.r3">[3]</xref>&#x000a0;Shared decision-making is recommended in such situations as the data is limited and the risk of malignant progression increases compared to other hypogonadal men without prostate cancer.</p>
        <p>
<bold>Typical Dosage Schedule</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Oral capsule (testosterone undecanoate): 112.5 mg, 158 mg, 198 mg, or 237 mg. The initial recommended starting dose is 237 mg or 225 mg&#x000a0;2 times daily with food.&#x000a0;Dosing may&#x000a0;be adjusted to a minimum of 158 mg twice daily and a maximum of 396 mg 2 times daily based on serum testosterone drawn 6 hours following the morning dose after at least 7 days of therapy or following dose adjustment and periodically after that. Take&#x000a0;the drug with food.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Clomiphene citrate: 25 to 50 mg daily or every other day for 25 days with 5 days off. (Should not be used in men with elevated LH levels.) This is an off-label indication for clomiphene.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Human chorionic gonadotropin for selected cases of hypogonadotropic hypogonadism in males (Should not be used in men with elevated LH levels.)
<list list-type="bullet"><list-item><p>500 to 1,000 USP units&#x000a0;3 times a week for&#x000a0;3 weeks, followed by the same dose twice a weekfor&#x000a0;3 weeks.&#x000a0;</p></list-item><list-item><p>4,000 USP units&#x000a0;3 times weekly for&#x000a0;6 to&#x000a0;9 months, following which the dosage may bereduced to 2,000 USP units&#x000a0;3 times weekly for an additional&#x000a0;3 months</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Nasal gel: 5.5 mg/actuation (7.32 g)&#x000a0;One dose in each nostril&#x000a0;3 times daily.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Transdermal gel
<list list-type="bullet"><list-item><p>25 mg/2.5 g (1%) in 2.5 g</p></list-item><list-item><p>50 mg/5 g (1%) in 5 g</p></list-item><list-item><p>20.25 mg/1.25 g (1.62%) in 1.25 g</p></list-item><list-item><p>40.5 mg/2.5 g (1.62%) in 2.5 g</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pump
<list list-type="bullet"><list-item><p>12.5 mg/actuation (1%) in 75 g</p></list-item><list-item><p>20.25 mg/actuation (1.62%) in 75 g</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Transdermal patch 24 h: 2 mg/24 h in each patch (pack of 60 patches); 4 mg/24 h in each patch (pack of 30 patches). (Not to be used on the scrotum)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Transdermal solution: 30 mg/actuation (90 mL); can be dosed from 30 mg to 90 mg daily applied to the axilla.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Implant: 75 mg pellet. The usual dosage is 2 to 6 pellets every 3 to 6 months.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Intramuscular
<list list-type="bullet"><list-item><p>Testosterone cypionate: Depo 100 mg/mL (10 mL); 200 mg/mL (1 mL, 10 mL)</p></list-item><list-item><p>Testosterone enanthate: 200 mg/mL (5 mL)</p></list-item><list-item><p>Testosterone undecanoate 750 mg/3 mL (3 mL)</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Subcutaneous injection 50 mg/0.5 mL (0.5 mL); 75 mg/0.5 mL (0.5 mL); 100 mg/0.5 mL (0.5 mL) in an autoinjector.</p>
          </list-item>
        </list>
        <p>For more information on treating male hypogonadism, see our companion StatPearls reference article on "Male Hypogonadism" and the American Urological Association Guideline: Evaluation and Management of Testosterone Deficiency (2018).<xref ref-type="bibr" rid="article-17525.r2">[2]</xref><xref ref-type="bibr" rid="article-17525.r3">[3]</xref></p>
      </sec>
      <sec id="article-17525.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Due to exogenous testosterone's many formulations, clinicians must monitor&#x000a0;for different adverse effects at each visit. Buccal tablets can irritate gums and oral mucosa. Testosterone gels can get transferred to a woman or child who comes in contact with the gel. As a result, patients are advised to cover the application site with clothing and wash the skin before having skin-to-skin contact to avoid transmission. Testosterone patches can cause skin reactions, and injectables can cause mood, energy, and libido fluctuations.&#x000a0;</p>
        <p>In 2015, the FDA concluded a possible increased cardiovascular risk associated with testosterone use existed, requiring labeling change to inform the public. Testosterone use has been associated with erythrocytosis related to hematocrit, increasing the risk of venous thromboembolism.<xref ref-type="bibr" rid="article-17525.r21">[21]</xref>&#x000a0;</p>
        <p>Serum PSA levels can increase in response to testosterone treatment, so it is essential to rule out prostate cancer before starting therapy, as&#x000a0;testosterone replacement can worsen the disease process. Patients on replacement therapy require reevaluation for prostate cancer at three months and one year after beginning treatment.<xref ref-type="bibr" rid="article-17525.r22">[22]</xref>&#x000a0;</p>
        <p>Testosterone has had no significant effects on lower urinary tract symptoms and BPH.<xref ref-type="bibr" rid="article-17525.r21">[21]</xref>&#x000a0;Clinicians need to address testosterone therapy's risks and benefits before initiating treatment.</p>
      </sec>
      <sec id="article-17525.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are several contraindications to androgen replacement therapy.<xref ref-type="bibr" rid="article-17525.r22">[22]</xref>&#x000a0;These include the following:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>History&#x000a0;of breast cancer</p>
          </list-item>
          <list-item>
            <p>Prostate cancer</p>
          </list-item>
          <list-item>
            <p>Uncontrolled heart failure</p>
          </list-item>
          <list-item>
            <p>Myocardial infarction or cerebrovascular accident within&#x000a0;the past&#x000a0;six&#x000a0;months</p>
          </list-item>
          <list-item>
            <p>Untreated obstructive sleep apnea</p>
          </list-item>
          <list-item>
            <p>Hematocrit&#x000a0;over 50%</p>
          </list-item>
          <list-item>
            <p>Men planning fertility</p>
          </list-item>
          <list-item>
            <p>A palpable undiagnosed prostate nodule</p>
          </list-item>
          <list-item>
            <p>An elevated PSA above 4 ng/mL</p>
          </list-item>
          <list-item>
            <p>An increased&#x000a0;PSA level above 4 ng/mL in high-risk patients, including African Americans and men with a first-degree relative with prostate cancer</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17525.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Lab tests needed before starting androgen replacement include hemoglobin (Hgb), hematocrit (Hct), liver function tests (LFTs), lipid panels, DRE, PSA level, prolactin, 2-morning testosterone levels, and consider a DEXA scan.</p>
        <p>The usual goal of therapy is to achieve a mid-week or median testosterone level in the middle third of the normal range. Some experts recommend checking a peak testosterone level&#x000a0;2 days after an IM injection.<xref ref-type="bibr" rid="article-17525.r3">[3]</xref> Checking levels should usually wait for 30 days after starting therapy to allow for full therapeutic stabilization. The dosage can be adjusted accordingly. If a supernormal level is found, a smaller dosage is suggested. Then, the process is repeated until optimal levels are achieved.&#x000a0;</p>
        <p>Monitoring should be&#x000a0;performed as follows:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>One month after treatment: testosterone level</p>
          </list-item>
          <list-item>
            <p>Three to&#x000a0;6 months after treatment during the first year: testosterone level, LFTs, lipid profile, PSA, DRE, estradiol,&#x000a0;Hgb, and&#x000a0;Hct, blood pressure</p>
          </list-item>
          <list-item>
            <p>Annually after one year: testosterone level, LFTs, lipid profile, DRE, PSA, estradiol,&#x000a0;Hgb, and Hct, blood pressure<xref ref-type="bibr" rid="article-17525.r2">[2]</xref><xref ref-type="bibr" rid="article-17525.r3">[3]</xref><xref ref-type="bibr" rid="article-17525.r22">[22]</xref></p>
          </list-item>
        </list>
        <p>If there is no symptomatic improvement after&#x000a0;6 months of optimal testosterone replacement, consideration should be given to stopping testosterone supplementation therapy.<xref ref-type="bibr" rid="article-17525.r2">[2]</xref><xref ref-type="bibr" rid="article-17525.r3">[3]</xref></p>
        <p>An increase in PSA level greater than 25% or 1.4 ng/mL within any 12-month&#x000a0;period should&#x000a0;be repeated and, if confirmed, considered suspicious.</p>
        <p>If the hematocrit rises above 54%, stop therapy as soon as possible.<xref ref-type="bibr" rid="article-17525.r2">[2]</xref><xref ref-type="bibr" rid="article-17525.r3">[3]</xref><xref ref-type="bibr" rid="article-17525.r22">[22]</xref>&#x000a0;</p>
        <p>It is important to look for signs of sleep apnea on annual follow-up visits.</p>
        <p>DEXA scans should be repeated 1 to 2 years after initiating therapy in hypogonadal men with osteoporosis.<xref ref-type="bibr" rid="article-17525.r23">[23]</xref>&#x000a0;</p>
        <p>Hyperestrogenism can be an adverse effect of replacement therapy because testosterone undergoes&#x000a0;aromatization to estrogen.<xref ref-type="bibr" rid="article-17525.r24">[24]</xref>&#x000a0;Aromatase inhibitors may be necessary. Therefore, estradiol levels in men need to be assessed periodically to rule out hyperestrogenism.</p>
        <p>The clinical team&#x000a0;needs to monitor patients receiving testosterone therapy regularly, and they should discontinue treatment for those who fail to follow up.</p>
        <p>For more information on the monitoring and follow-up of male hypogonadism, see our companion StatPearls reference article on "Male Hypogonadism" and the American Urological Association Guideline: Evaluation and Management of Testosterone Deficiency (2018).<xref ref-type="bibr" rid="article-17525.r16">[16]</xref><xref ref-type="bibr" rid="article-17525.r20">[20]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-17525.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There are no reports of acute overdosage toxicity with testosterone. Call the local poison control center for up-to-date guidance at 1-800-222-1222.</p>
      </sec>
      <sec id="article-17525.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Physicians, advanced practice practitioners, pharmacists, and nurses operating as interprofessional healthcare teams must know the risks, benefits, and contraindications of testosterone replacement therapy.&#x000a0;There are conflicting trials on the cardiovascular risks of testosterone therapy, most notably the TOM (Testosterone in Older Men) trial and the TEAAM&#x000a0;(Testosterone's Effects on Atherosclerosis Progression in Aging Men) trials.</p>
        <p>Low testosterone levels have correlated with an increased risk of coronary artery disease.<xref ref-type="bibr" rid="article-17525.r25">[25]</xref><xref ref-type="bibr" rid="article-17525.r26">[26]</xref>&#x000a0;A study published in JAMA in 2017 found that testosterone replacement&#x000a0;was associated with a lower risk of cardiovascular outcomes.<xref ref-type="bibr" rid="article-17525.r27">[27]</xref>&#x000a0;</p>
        <p>The American Association of Clinical Endocrinologists&#x000a0;(AACE) issued a guideline in response to the 2015 FDA labeling requirement on cardiovascular risk.&#x000a0;The guideline stated that there is no compelling evidence that testosterone therapy increases cardiovascular risk.<xref ref-type="bibr" rid="article-17525.r28">[28]</xref>&#x000a0;On&#x000a0;the&#x000a0;other&#x000a0;hand,&#x000a0;testosterone deficiency correlates with falls, sarcopenia, frailty, osteopenia, and osteoporosis.<xref ref-type="bibr" rid="article-17525.r29">[29]</xref>&#x000a0;</p>
        <p>Clinicians must prescribe androgen replacement therapy using a risk-benefit assessment of the patient's clinical needs and risk of adverse reactions. There should be a clear, expected symptomatic benefit to justify continuing treatment beyond the initial clinical trial period of 3 to 6 months. They should employ shared decision-making techniques that include the patient, pharmacist, and nurses and set realistic goals as well as parameters for stopping therapy.</p>
        <p>Pharmacists should verify dosing, check for potential interactions, and provide thorough counseling for drug administration, which will vary depending on the treatment modality and formulation chosen.</p>
        <p>Nurses can also counsel patients on dosing and administration and assess treatment effectiveness. Both pharmacists and nurses must inform the prescriber of any concerns they may encounter, so open communication channels and shared decision-making&#x000a0;among team members are vital. Monitoring of the patient by the interprofessional team will result in the best outcomes with the fewest adverse events.</p>
      </sec>
      <sec id="article-17525.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17525&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17525">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17525/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17525">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17525.s11">
        <title>References</title>
        <ref id="article-17525.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Metter</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Tobin</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blackman</surname>
                <given-names>MR</given-names>
              </name>
              <collab>Baltimore Longitudinal Study of Aging</collab>
            </person-group>
            <article-title>Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>86</volume>
            <issue>2</issue>
            <fpage>724</fpage>
            <page-range>724-31</page-range>
            <pub-id pub-id-type="pmid">11158037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mulhall</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Trost</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Brannigan</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Kurtz</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Redmon</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Chiles</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Lightner</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Miner</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Platz</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Ramanathan</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Evaluation and Management of Testosterone Deficiency: AUA Guideline.</article-title>
            <source>J Urol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>200</volume>
            <issue>2</issue>
            <fpage>423</fpage>
            <page-range>423-432</page-range>
            <pub-id pub-id-type="pmid">29601923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sizar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <chapter-title>Hypogonadism</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>6</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">30422528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vermeulen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of hypogonadism in the aging male.</article-title>
            <source>Aging Male</source>
            <year>2002</year>
            <month>Sep</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>170</fpage>
            <page-range>170-6</page-range>
            <pub-id pub-id-type="pmid">12471777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carnegie</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of hypogonadism: clinical assessments and laboratory tests.</article-title>
            <source>Rev Urol</source>
            <year>2004</year>
            <volume>6 Suppl 6</volume>
            <issue>Suppl 6</issue>
            <fpage>S3</fpage>
            <page-range>S3-8</page-range>
            <pub-id pub-id-type="pmid">16985909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Recent studies on the mechanism of action of testosterone.</article-title>
            <source>N Engl J Med</source>
            <year>1972</year>
            <month>Dec</month>
            <day>21</day>
            <volume>287</volume>
            <issue>25</issue>
            <fpage>1284</fpage>
            <page-range>1284-91</page-range>
            <pub-id pub-id-type="pmid">4119318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Kiang</surname>
                <given-names>TKL</given-names>
              </name>
              <name>
                <surname>Ensom</surname>
                <given-names>MHH</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics, safety, and patient acceptability of subcutaneous versus intramuscular testosterone injection for gender-affirming therapy: A pilot study.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2018</year>
            <month>Mar</month>
            <day>15</day>
            <volume>75</volume>
            <issue>6</issue>
            <fpage>351</fpage>
            <page-range>351-358</page-range>
            <pub-id pub-id-type="pmid">29367424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ramasamy</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Indications for the use of human chorionic gonadotropic hormone for the management of infertility in hypogonadal men.</article-title>
            <source>Transl Androl Urol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>7</volume>
            <issue>Suppl 3</issue>
            <fpage>S348</fpage>
            <page-range>S348-S352</page-range>
            <pub-id pub-id-type="pmid">30159241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Delu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kiltz</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kuznetsov</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Trussell</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Clomiphene citrate improved testosterone and sperm concentration in hypogonadal males.</article-title>
            <source>Syst Biol Reprod Med</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>66</volume>
            <issue>6</issue>
            <fpage>364</fpage>
            <page-range>364-369</page-range>
            <pub-id pub-id-type="pmid">33043679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huijben</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lock</surname>
                <given-names>MTWT</given-names>
              </name>
              <name>
                <surname>de Kemp</surname>
                <given-names>VF</given-names>
              </name>
              <name>
                <surname>de Kort</surname>
                <given-names>LMO</given-names>
              </name>
              <name>
                <surname>van Breda</surname>
                <given-names>HMK</given-names>
              </name>
            </person-group>
            <article-title>Clomiphene citrate for men with hypogonadism: a systematic review and meta-analysis.</article-title>
            <source>Andrology</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>451</fpage>
            <page-range>451-469</page-range>
            <pub-id pub-id-type="pmid">34933414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Puia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pricop</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of Clomiphene Citrate for Improving Sperm Concentration: A Literature Review and Meta-Analysis.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>May</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>e25093</fpage>
            <pub-id pub-id-type="pmid">35733503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wenker</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Dupree</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Langille</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Kovac</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ramasamy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lamb</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Lipshultz</surname>
                <given-names>LI</given-names>
              </name>
            </person-group>
            <article-title>The Use of HCG-Based Combination Therapy for Recovery of Spermatogenesis after Testosterone Use.</article-title>
            <source>J Sex Med</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>1334</fpage>
            <page-range>1334-7</page-range>
            <pub-id pub-id-type="pmid">25904023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>BQ</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Oral testosterone undecanoate (Andriol) supplement therapy improves the quality of life for men with testosterone deficiency.</article-title>
            <source>Aging Male</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>86</fpage>
            <page-range>86-93</page-range>
            <pub-id pub-id-type="pmid">12898792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swerdloff</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Kaminetsky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gittelman</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Longstreth</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Dudley</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Danoff</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2020</year>
            <month>Aug</month>
            <day>01</day>
            <volume>105</volume>
            <issue>8</issue>
            <fpage>2515</fpage>
            <page-range>2515-31</page-range>
            <pub-id pub-id-type="pmid">32382745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Honig</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gittelman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaminetsky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Amory</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Rohowsky</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dudley</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Woun Seo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Newmark</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Swerdloff</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety.</article-title>
            <source>J Sex Med</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>12</issue>
            <fpage>1750</fpage>
            <page-range>1750-1758</page-range>
            <pub-id pub-id-type="pmid">36272969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reddy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rivero</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Muthigi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ramasamy</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Patient Satisfaction After Switching to Jatenzo (Oral Testosterone Undecanoate): Update on an Open-label, Single-arm Clinical Trial.</article-title>
            <source>Eur Urol Focus</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-19</page-range>
            <pub-id pub-id-type="pmid">36064541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Britto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fitzpatrick</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McWhirter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Testino</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Zumbrunnen</surname>
                <given-names>TL</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and relative bioavailability of absorbed testosterone after administration of a 1.62% testosterone gel to different application sites in men with hypogonadism.</article-title>
            <source>Endocr Pract</source>
            <year>2011</year>
            <season>Jul-Aug</season>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>574</fpage>
            <page-range>574-83</page-range>
            <pub-id pub-id-type="pmid">21454244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Snyder</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Treatment of male hypogonadism with testosterone enanthate.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>1980</year>
            <month>Dec</month>
            <volume>51</volume>
            <issue>6</issue>
            <fpage>1335</fpage>
            <page-range>1335-9</page-range>
            <pub-id pub-id-type="pmid">6777395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schubert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Minnemann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>H&#x000fc;bler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rouskova</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Christoph</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oettel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ernst</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mellinger</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Krone</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Jockenh&#x000f6;vel</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>89</volume>
            <issue>11</issue>
            <fpage>5429</fpage>
            <page-range>5429-34</page-range>
            <pub-id pub-id-type="pmid">15531493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calof</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Kenny</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Urban</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Tenover</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Bhasin</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials.</article-title>
            <source>J Gerontol A Biol Sci Med Sci</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>60</volume>
            <issue>11</issue>
            <fpage>1451</fpage>
            <page-range>1451-7</page-range>
            <pub-id pub-id-type="pmid">16339333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ponce</surname>
                <given-names>OJ</given-names>
              </name>
              <name>
                <surname>Spencer-Bonilla</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Alvarez-Villalobos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Serrano</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Singh-Ospina</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rodriguez-Gutierrez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Salcido-Montenegro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Benkhadra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Prokop</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Bhasin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brito</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>The efficacy and adverse events of testosterone replacement therapy in hypogonadal men: A systematic review and meta-analysis of randomized, placebo-controlled trials.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2018</year>
            <month>Mar</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">29562341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhasin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brito</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Hodis</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Swerdloff</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Yialamas</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2018</year>
            <month>May</month>
            <day>01</day>
            <volume>103</volume>
            <issue>5</issue>
            <fpage>1715</fpage>
            <page-range>1715-1744</page-range>
            <pub-id pub-id-type="pmid">29562364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Golds</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Houdek</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Arnason</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Male Hypogonadism and Osteoporosis: The Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health.</article-title>
            <source>Int J Endocrinol</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>4602129</fpage>
            <pub-id pub-id-type="pmid">28408926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Reilly</surname>
                <given-names>WG</given-names>
              </name>
            </person-group>
            <article-title>High estrogen in men after injectable testosterone therapy: the low T experience.</article-title>
            <source>Am J Mens Health</source>
            <year>2015</year>
            <month>May</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>229</fpage>
            <page-range>229-34</page-range>
            <pub-id pub-id-type="pmid">24928451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosano</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Sheiban</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Massaro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pagnotta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marazzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vitale</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mercuro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Volterrani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aversa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fini</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Low testosterone levels are associated with coronary artery disease in male patients with angina.</article-title>
            <source>Int J Impot Res</source>
            <year>2007</year>
            <season>Mar-Apr</season>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>176</fpage>
            <page-range>176-82</page-range>
            <pub-id pub-id-type="pmid">16943795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Rui</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Low testosterone level in middle-aged male patients with coronary artery disease.</article-title>
            <source>Eur J Intern Med</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>22</volume>
            <issue>6</issue>
            <fpage>e133</fpage>
            <page-range>e133-6</page-range>
            <pub-id pub-id-type="pmid">22075298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheetham</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>An</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Niu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sidney</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Quesenberry</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>VanDenEeden</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Association of Testosterone Replacement With Cardiovascular Outcomes Among Men With Androgen Deficiency.</article-title>
            <source>JAMA Intern Med</source>
            <year>2017</year>
            <month>Apr</month>
            <day>01</day>
            <volume>177</volume>
            <issue>4</issue>
            <fpage>491</fpage>
            <page-range>491-499</page-range>
            <pub-id pub-id-type="pmid">28241244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goodman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Guay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dandona</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dhindsa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Faiman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>GR</given-names>
              </name>
              <collab>AACE Reproductive Endocrinology Scientific Committee</collab>
            </person-group>
            <article-title>AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF TESTOSTERONE AND CARDIOVASCULAR RISK.</article-title>
            <source>Endocr Pract</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>21</volume>
            <issue>9</issue>
            <fpage>1066</fpage>
            <page-range>1066-73</page-range>
            <pub-id pub-id-type="pmid">26355962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17525.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hsu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cumming</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Handelsman</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Testosterone, frailty and physical function in older men.</article-title>
            <source>Expert Rev Endocrinol Metab</source>
            <year>2018</year>
            <month>May</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>159</fpage>
            <page-range>159-165</page-range>
            <pub-id pub-id-type="pmid">30058896</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
